Close
Sharma SK, Bagshawe KD, Begent RH. Advances in antibody-directed enzyme prodrug therapy. Curr Opin Investig Drugs 2005 Jun;6(6):611-5.
Mayer A, Sharma SK, Tolner B, Minton NP, Purdy D, Amlot P, Tharakan G, Begent RH, Chester KA (2004) Modifying an immunogenic epitope on a therapeutic protein: a step towards an improved system for antibody-directed enzyme prodrug therapy (ADEPT). Br J Cancer 90: 2402-2410
Napier MP, Sharma SK, Springer CJ, Bagshawe KD, Green AJ, Martin J, Stribbling SM, Cushen N, O'Malley D, Begent RH (2000) Antibody-directed enzyme prodrug therapy: efficacy and mechanism of action in colorectal carcinoma. Clin Cancer Res 6: 765-772
Pedley RB, Sharma SK, Boxer GM, Boden R, Stribbling SM, Davies L, et al. Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent. Cancer Res 1999 Aug 15;59(16):3998-4003.
Sharma SK, Bagshawe KD, Burke PJ, Boden JA, Rogers GT, Springer CJ, et al. Galactosylated antibodies and antibody-enzyme conjugates in antibody-directed enzyme prodrug therapy. Cancer 1994 Feb 1;73(3 Suppl):1114-20.
Sharma SK, Bagshawe KD, Melton RG, Sherwood RF. Human immune response to monoclonal antibody-enzyme conjugates in ADEPT pilot clinical trial. Cell Biophys 1992 Aug;21(1-3):109-20
Bagshawe KD, Sharma SK, Springer CJ, Antoniw P, Boden JA, Rogers GT, et al. Antibody directed enzyme prodrug therapy (ADEPT): clinical report. Dis Markers 1991 May;9(3-4):233-8.
Bagshawe KD, Springer CJ, Searle F, Antoniw P, Sharma SK, Melton RG, et al. A cytotoxic agent can be generated selectively at cancer sites. Br J Cancer 1988 Dec;58(6):700-3.
Bagshawe KD, Sharma SK, Begent RH. Antibody-directed enzyme prodrug therapy (ADEPT) for cancer. Expert Opin Biol Ther 2004 Nov;4(11):1777-89.
Francis RJ, Mather SJ, Chester K, Sharma SK, Bhatia J, Pedley RB, et al. Radiolabelling of glycosylated MFE-23::CPG2 fusion protein (MFECP1) with 99mTc for quantitation of tumour antibody-enzyme localisation in antibody-directed enzyme pro-drug therapy (ADEPT). Eur J Nucl Med Mol Imaging 2004 Aug;31(8):1090-6.
Medzihradszky KF, Spencer DI, Sharma SK, Bhatia J, Pedley RB, Read DA, et al. Glycoforms obtained by expression in Pichia pastoris improve cancer targeting potential of a recombinant antibody-enzyme fusion protein. Glycobiology 2004 Jan;14(1):27-37.
Pedley RB, Sharma SK, Hawkins RE, Chester KA. Antibody-directed enzyme-prodrug therapy. Methods Mol Med 2004;90:491-514
Francis RJ, Sharma SK, Springer C, Green AJ, Hope-Stone LD, Sena L, et al. A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours. Br J Cancer 2002 Sep 9;87(6):600-7.
Spencer DI, Robson L, Purdy D, Whitelegg NR, Michael NP, Bhatia J, et al. A strategy for mapping and neutralizing conformational immunogenic sites on protein therapeutics. Proteomics 2002 Mar;2(3):271-9.
Webley SD, Francis RJ, Pedley RB, Sharma SK, Begent RH, Hartley JA, et al. Measurement of the critical DNA lesions produced by antibody-directed enzyme prodrug therapy (ADEPT) in vitro, in vivo and in clinical material. Br J Cancer 2001 Jun 15;84(12):1671-6.
Bhatia J, Sharma SK, Chester KA, Pedley RB, Boden RW, Read DA, et al. Catalytic activity of an in vivo tumor targeted anti-CEA scFv::carboxypeptidase G2 fusion protein. Int J Cancer 2000 Feb 15;85(4):571-7.
Bagshawe KD, Sharma SK, Burke PJ, Melton RG, Knox RJ. Developments with targeted enzymes in cancer therapy. Curr Opin Immunol 1999 Oct;11(5):579-83.
Martin J, Stribbling SM, Poon GK, Begent RH, Napier M, Sharma SK, et al. Antibody-directed enzyme prodrug therapy: pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trial. Cancer Chemother Pharmacol 1997;40(3):189-201.
Bagshawe KD, Sharma SK. Cyclosporine delays host immune response to antibody enzyme conjugate in ADEPT. Transplant Proc 1996 Dec;28(6):3156-8.
Sharma SK, Bagshawe KD, Melton RG, Begent RH. Effect of cyclosporine on immunogenicity of a bacterial enzyme carboxypeptidase G2 in ADEPT. Transplant Proc 1996 Dec;28(6):3154-5.
Sharma SK, Bagshawe KD, Melton RG, Sherwood RF. Human immune response to monoclonal antibody-enzyme conjugates in ADEPT pilot clinical trial. Cell Biophys 1992 Aug;21(1-3):109-20
Sharma SK, Bagshawe KD, Burke PJ, Boden RW, Rogers GT. Inactivation and clearance of an anti-CEA carboxypeptidase G2 conjugate in blood after localisation in a xenograft model. Br J Cancer 1990 May;61(5):659-62